Figure 2.

Management of patients with inadequate response to standard UDCA first-line treatment. The real-world management of 116 patients with inadequate response to standard first-line UDCA treatment according to at least one criterion is depicted, including patients without treatment modification (n = 39), increase of UDCA dosage (n = 35), addition of glucocorticoids (n = 6), bezafibrates (n = 28) or obeticholic acid (n = 4). Treatment response rates according to Paris-I, Paris-II, and Barcelona criteria and ALP levels ≤ 1.67 × ULN and bilirubin ≤ 1 × ULN at 12 months after treatment modification, respectively; continuation of UDCA-monotherapy was analyzed. * p < 0.05, ** p < 0.01, not significant (ns) = p ≥ 0.05.